Short interest for Staar Surgical gives investors a sense of the degree to which investors are betting on the decline of Staar Surgical's stock. Short interest data is updated every two weeks.

Staar Surgical Stock (NASDAQ:STAA), Short Interest Report

Staar Surgical

Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.

xr:d:DAFih-sWqhI:2,j:46865321670,t:23051015

News

Intraday Update

Markets

Movers

AFIB

AFRM

ALAB

AMRC

AMRK

AOSL

APEI

ARKO

BROS

CLOV

CPNG

CRCT

CRUS

DTCK

ELAN

FLYW

GMED

Hannon Armstrong Sustainable Infrastructure Capital

HASI

INOD

INSP

ISUN

LAZR

LYFT

MASI

MCRB

MXCT

MYGN

NIVF

PWSC

QLYS

REBN

RPTX

SATS

SHLS

SHOP

SIGA

SMLR

STAA

SWIM

TEVA

TIVC

TMCI

TOST

TRIP

TWLO

UBER

UPST

VECO

VLCN

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Price Target

Small Cap

Analyst Ratings

Trading Ideas

AAPL

FFIV

GATO

TEAM

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Apple To $210? Here Are 10 Top Analyst Forecasts For Thursday

eyeball

Earnings

Guidance

Health Care

General

STAAR Surgical reports Q1 2024 net sales surpassing $77 million, with U.S. ICL sales hitting $5 million, the highest since FDA approval in 2022. CEO anticipates fiscal 2024 sales expected at the higher end of $335-340 million outlook.

Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus

Staar Surgical Co

Needham analyst David Saxon reiterates Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Staar Surgical

Shares of Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue <a href="https://www.benzinga.com/news/earnings/24/05/38682848/upstart-q1-earnings-revenue-beat-eps-beat-targeting-positive-ebitda-in-2024-and-more">guidance below estimates</a>.
Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Upstart expects second-quarter revenue of approximately $125 million versus estimates of $140.83 million. The company anticipates a second-quarter adjusted EBITDA loss of approximately $25 million.
Upstart shares dipped 10.3% to $21.96 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reborn Coffee, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) shares jumped 132.9% to $4.0297 after the company announced a significant expansion into the China market through a strategic Master License Agreement with IAID Co.</li>
<li>iSun, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISUN#NASDAQ">ISUN</a>) gained 49% to $0.1966.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) jumped 36.4% to $1.48.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) rose 34% to $1.4099.</li>
<li>Innodata Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares gained 31.5% to $8.86 after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Cricut, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) gained 31% to $7.25 after the company reported better-than-expected first-quarter GAAP EPS results.</li>
<li>MaxCyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) rose 27.6% to $5.01 following upbeat quarterly results.</li>
<li>Ameresco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NASDAQ">AMRC</a>) gained 27.6% to $28.47 following strong quarterly results.</li>
<li>Davis Commodities Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTCK#NASDAQ">DTCK</a>) rose 26.8% to $1.5580</li>
<li>Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) surged 26.5% to $17.11 following strong quarterly earnings.</li>
<li>American Public Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) rose 23.3% to $18.71 following upbeat quarterly results.</li>
<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) gained 23.3% to $63.35 after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance.</li>
<li>Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) jumped 21.6% to $25.25 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>PowerSchool Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWSC#NYSE">PWSC</a>) gained 21.2% to $20.17 following a report suggesting Bain is pursuing a takeover of the company.</li>
<li>Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) rose 21.1% to $24.02 following better-than-expected first-quarter earnings.</li>
<li>Arko Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKO#NYSE">ARKO</a>) gained 20.3% to $5.15 following first-quarter earnings.</li>
<li>Latham Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) gained 19% to $3.5609 following strong first-quarter earnings.</li>
<li>Hyster-Yale Materials Handling, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) surged 18.2% to $69.74 following UPBEAT first-quarter earnings.</li>
<li>Alpha and Omega Semiconductor Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) jumped 17.7% to $26.22 after reporting strong quarterly results.</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) gained 17.2% to $1.1529 after declining over 6% on Tuesday.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) gained 15.8% to $36.19 after the company reported better-than-expected first-quarter financial results and issued FY24 EPS guidance above estimates.</li>
<li>Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) climbed 15.5% to $32.82 after the company reported better-than-expected first-quarter financial results and raised its FY24 revenue guidance.</li>
<li>Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) gained 15% to $83.93 following better-than-expected first-quarter financial results.</li>
<li>RingCentral, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) rose 14.8% to $34.42 after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance.</li>
<li>Luminar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) rose 14.5% to $1.89 as the company posted a narrower-than-expected quarterly loss.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) gained 14.2% to $27.09 after the company reported better-than-expected quarterly sales results.</li>
<li>Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NASDAQ">HASI</a>) gained 13.9% to $29.84 following upbeat earnings.</li>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) rose 13% to $15.75 after the company reported mixed first quarter financial results.</li>
<li>Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>) gained 11.7% to $3.6650 after the company posted better-than-expected results for its first quarter.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) gained 10.1% to $90.01 after the company reported first quarter financial results.</li>
<li>Cirrus Logic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRUS#NASDAQ">CRUS</a>) jumped 9.6% to $99.93 as the company posted better-than-expected results for its fourth quarter.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares gained 9.5% to $0.81 after the company reported better than expected first-quarter financial results.</li>
<li>Lyft, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) gained 8.8% to $18.08 following better-than-expected first-quarter results.</li>
<li>Veeco Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) rose 6.9% to $40.08 following upbeat results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Treace Medical Concepts, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) shares dipped 60.8% to $4.3650 after the company reported first-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>DoubleVerify Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) fell 38.5% to $18.79 after the company reported first-quarter financial results.</li>
<li>Inspire Medical Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>) fell 34.3% to $161.35 following first-quarter results.</li>
<li>Definitive Healthcare Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) dipped 32.2% to $4.9150 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) fell 31.1% to $0.7653 following quarterly results.</li>
<li>Tripadvisor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) fell 28.4% to $18.24 after Liberty Tripadvisor and the Special Committee ceased discussions with third parties with respect to a potential transaction.</li>
<li>ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) shares fell 25.2% to $11.98 after the company reported first-quarter financial results and issued second-quarter guidance below estimates.</li>
<li>LegalZoom.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LZ#NASDAQ">LZ</a>) dipped 23.3% to $9.35 after the company reported worse-than-expected first-quarter financial results and issued second-quarter revenue guidance below estimates.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) fell 22.7% to $21.78 after the company reported worse-than-expected first-quarter financial results.</li>
<li>Grocery Outlet Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) dipped 22.2% to $20.17 after the company reported worse-than-expected first-quarter adjusted EPS results.</li>
<li>Flywire Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYW#NASDAQ">FLYW</a>) shares declined 21.7% to $16.08 after the company reported worse-than-expected first-quarter EPS results and issued second-quarter revenue guidance below estimates.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) dipped 20.6% to $8.31 following first-quarter results.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) fell 19.8% to $61.76 following first-quarter earnings..</li>
<li>Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) dipped 18.6% to $37.26 following first-quarter earnings..</li>
<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) fell 17.1% to $0.1020 after jumping 15% on Tuesday. Nasdaq, last week, notified the company that it has not regained compliance with listing rule 5550(a)(2).</li>
<li>Shoals Technologies Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) shares fell 14.1% to $7.56 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Masimo Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) fell 13.8% to $117.23 following first-quarter earnings. The company&#8217;s second-quarter guidance midpoint was below consensus estimates.</li>
<li>EchoStar Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATS#NASDAQ">SATS</a>) dipped 13.6% to $14.99 following worse-than-expected first-quarter financial results.</li>
<li>STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) dipped 11.8% to $41.10 following quarterly results.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) shares declined 11.8% to $0.26 after the company reported a year-over-year decrease in first-quarter sales results.</li>
<li>Qualys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) fell 10.1% to $149.21 after the company reported first-quarter earnings and issued second-quarter revenue guidance below estimates.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) fell 9.1% to $31.74 following third-quarter earnings.</li>
<li>Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) dipped 8.6% to $64.40. Uber posted weaker-than-expected fiscal first-quarter financial results.</li>
<li>Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>) fell 7.8% to $21.78 after the company reported mixed first-quarter financial results.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares declined 6.3% to $71.37 following first-quarter results.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) shares declined 6.2% to $41.56 following first-quarter results.</li>
<li>A-Mark Precious Metals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRK#NASDAQ">AMRK</a>) shares fell 5.5% to $38.14 following fiscal third quarter 2024 results.</li>
<li>Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) shares fell 5.5% to $59.86 following first-quarter results.</li>
<li>OPKO Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) shares fell 5.4% to $1.23 after the company reported worse-than-expected first-quarter financial results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38702433/airbnb-gears-up-for-q1-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Airbnb Gears Up For Q1 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

WIIM

STAAR Surgical shares are trading lower after the company reported Q1 financial results.

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $46 to $43.

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $43

Piper Sandler analyst Matt O'Brien maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Neutral and raises the price target from $33 to $40.

Piper Sandler Maintains Neutral on Staar Surgical, Raises Price Target to $40

Analysts' ratings for Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.43, a high estimate of $55.00, and a low estimate of $33.00. This current average has increased by 10.66% from the previous average price target of $42.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1715173223_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Staar Surgical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$46.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Staar Surgical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
<h2>All You Need to Know About Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Staar Surgical: Financial Performance Dissected</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Staar Surgical showcased positive performance, achieving a revenue growth rate of 19.09% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Staar Surgical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.17%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.03%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Staar Surgical's ROA stands out, surpassing industry averages. With an impressive ROA of 1.62%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Staar Surgical's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 7 Analyst Ratings Have To Say About Staar Surgical

Mizuho analyst Anthony Petrone maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Buy and raises the price target from $53 to $55.

Mizuho Maintains Buy on Staar Surgical, Raises Price Target to $55

Agreement is Largest Commitment to EVO ICL&#x2122; in the U.S.
STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer&#xAE; Lenses (EVO ICL&#x2122;) for myopia, astigmatism and presbyopia, today announces another milestone achieved on its U.S. Highway 93 go-to-market program – a strategic agreement with IQ Laser Vision, a leader in providing clear vision to clients with locations across California and Texas, and a top EVO ICL practice in North America.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240507036972/en/">https://www.businesswire.com/news/home/20240507036972/en/</a>
IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering. IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months. To support the transition and ramp up, STAAR Surgical and IQ Laser Vision will collaborate on marketing, education, practice development and clinical support activities to further elevate awareness of EVO ICL and substantially increase the availability of the lenses to all qualified patients across the IQ Laser Vision Family of Practices, which includes Scott Hyver Visioncare, Ellis Eye, and Mattioli Vision Professionals.
Tom Frinzi, Chair of the Board and CEO of STAAR Surgical, stated, "With the rapid growth of EVO ICL in the U.S., against the backdrop of a continued decline in laser vision correction procedures, it's becoming clear that lens-based procedures like EVO ICL are the future of refractive vision correction. STAAR Surgical made a strategic pivot late last year to shape that future – with a program that works double-duty to accelerate growth in leading EVO-ready practices, while working alongside them to test, learn and invest in the strategic drivers of that growth. Today, we're thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far. Dr. Lin is a renowned leader and pioneer in refractive eye surgery having performed over 70,000 refractive procedures and is one of the most experienced ICL surgeons in North America, having implanted over 1,000 ICLs over the past 12 months. Dr. Lin's deep and expansive expertise across refractive surgery makes his decision to offer EVO ICL as a primary option now all the more meaningful."

STAAR Surgical Announces Strategic Agreement With IQ Laser Vision In U.S.

Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.11) by 36.36 percent.

Earnings Beats

Staar Surgical Q1 2024 GAAP EPS $(0.07) Beats $(0.11) Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>JP Morgan raised the price target for F5, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ffiv#NASDAQ">FFIV</a>) from $197 to $205. JP Morgan analyst Samik Chatterjee maintained a Neutral rating. F5 shares fell 2.5% to close at $191.13 on Wednesday. <a href="https://www.benzinga.com/quote/FFIV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital boosted the price target for Gatos Silver, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gato#NYSE">GATO</a>) from $8 to $9. BMO Capital analyst Kevin O&#39;Halloran maintained a Market Perform rating. Gatos Silver shares gained 3.4% to close at $9.64 on Wednesday. <a href="https://www.benzinga.com/quote/GATO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut Walker &amp; Dunlop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wd#NYSE">WD</a>) price target from $130 to $95. Wedbush analyst Henry Coffey downgraded the stock from Outperform to Neutral. Walker &amp; Dunlop shares fell 4.3% to close at $92.64 on Wednesday. <a href="https://www.benzinga.com/quote/WD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for Apple Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) from $215 to $210. JP Morgan analyst Samik Chatterjee maintained an Overweight rating. Apple shares fell 1.1% to close at $167.78 on Wednesday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays raised Atlassian Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/team#NASDAQ">TEAM</a>) price target from $235 to $275. Barclays analyst Ryan Macwilliams upgraded the stock from Equal-Weight to Overweight. Atlassian shares rose 0.9% to close at $204.74 on Wednesday. <a href="https://www.benzinga.com/quote/TEAM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted STAAR Surgical Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/staa#NASDAQ">STAA</a>) price target from $45 to $53. Mizuho analyst Anthony Petrone maintained a Buy rating. STAAR Surgical shares fell 2.2% to close at $51.08 on Wednesday. <a href="https://www.benzinga.com/quote/STAA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for The Boeing Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ba#NYSE">BA</a>) from $210 to $190. B of A Securities analyst Ronald Epstein maintained a Neutral rating. Boeing shares fell 2% to close at $174.63 on Wednesday. <a href="https://www.benzinga.com/quote/BA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Berenberg raised Albemarle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) price target from $130 to $160. Berenberg analyst Andres Castanos Mollor upgraded the stock from Hold to Buy. Albemarle shares fell 1.2% to close at $127.65 on Wednesday. <a href="https://www.benzinga.com/quote/ALB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank raised Delta Air Lines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dal#NYSE">DAL</a>) price target from $50 to $60. Deutsche Bank analyst Michael Linenberg maintained a Buy rating. Delta Air shares fell 2.3% to close at $46.24 on Wednesday. <a href="https://www.benzinga.com/quote/DAL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) price target from $110 to $113. B of A Securities analyst Lorraine Hutchinson upgraded the stock from Neutral to Buy. NIKE shares fell 2.2% to close at $89.00 on Wednesday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/24/04/38198816/top-3-financial-stocks-that-are-ticking-portfolio-bombs"> Top 3 Financial Stocks That Are Ticking Portfolio Bombs </a>

Mizuho analyst Anthony Petrone maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Buy and raises the price target from $45 to $53.

Mizuho Maintains Buy on Staar Surgical, Raises Price Target to $53

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and raises the price target from $32 to $46.

Canaccord Genuity Maintains Hold on Staar Surgical, Raises Price Target to $46

STAAR Surgical shares are trading higher after the company recently issued strong preliminary Q1 net sales guidance.

Thursday,&nbsp;STAAR Surgical&nbsp;Company&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) reported preliminary net sales for the first quarter of 2024 of more than $77 million versus the consensus of $72.13 million, with U.S. ICL sales expected to be&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38086892/staar-surgical-announces-preliminary-net-sales-for-first-quarter-2024" rel="noreferrer noopener">$5 million for the quarter.</a>&nbsp;
This represents the company&#8217;s highest quarterly ICL sales in the U.S. since the company obtained U.S. FDA approval for the EVO ICL in March 2022.&nbsp;
&#8220;STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results, including a record quarter in the U.S.,&#8221; said Tom Frinzi, President and CEO.&nbsp;
&#8220;U.S. ICL sales were up approximately 20% sequentially to $5 million in the first quarter, which reflects early signs of our increased market focus. EMEA ICL sales were up approximately 11% year over year and ICL sales in our APAC region were up approximately 9%, including approximately 10% growth in China.
We are pleased by the first quarter performance across all major geographies and will provide further detail on our results and outlook during our upcoming earnings call, but at this time we believe our fiscal 2024 net sales can be at the higher end of our previously announced outlook range of $335 million to $340 million.&#8221;
Cash, cash equivalents, and investments available for sale were approximately $248 million, and accounts receivable were approximately $70 million as of March 29, 2024.
Needham&nbsp;writes that if the seasonal pattern of 2024 follows that of 2022 and 2023, it&#8217;s anticipated that 2024 revenues will likely approach $355 million.&nbsp;
Despite this, achieving STAAR Surgical&#8217;s revenue target for 2026 seems challenging, especially considering the necessary acceleration.&nbsp;
During a recent expert call, a doctor mentioned no expectation for an increase in their ICL mix.&nbsp;
While Needham analysts see the 2024 guidance as cautious, and anticipate a gradual domestic growth. Needham&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/STAA/analyst-ratings" rel="noreferrer noopener">maintains the Hold rating</a>.
Price Action: STAA shares are up 17.3% at $45.83 on the last check Thursday.
Photo by Gerax Sotelo on Unsplash

Shares of STAAR Surgical Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/staa#NASDAQ">STAA</a>) rose sharply during Thursday&rsquo;s session after the company issued strong preliminary first-quarter net sales guidance.
STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) shares climbed 130.1% to $2.9790. TCBP announced execution of non-binding letter of intent for acquisition of NK Platform Technologies.</li>
<li>Allurion Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alur#NASDAQ">ALUR</a>) gained 70% to $2.8801 after the company announced the commercial availability of its Virtual Care Suite in the United States. Also, Chardan Capital initiated coverage on the stock with a Buy rating and announced a $5 price target.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tvgn#NASDAQ">TVGN</a>) shares climbed 40.6% to $3.58. Tevogen Bio, on Wednesday, appointed Tapan V Shah as Head of Investor Relations and Corporate Development.</li>
<li>HWH International Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hwh#NASDAQ">HWH</a>) gained 38.8% to $2.1765.</li>
<li>Candel Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cadl#NASDAQ">CADL</a>) rose 36.3% to $2.2899 after the company announced interim data from the randomized phase 2 clinical trial of CAN-2409 in non-metastatic prostate cancer.</li>
<li>MacroGenics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgnx#NASDAQ">MGNX</a>) climbed 27.8% to $17.47. MacroGenics announced TAMARACK study data will not be presented at the ASCO Annual Meeting.</li>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) gained 27% to $2.22.</li>
<li>Reliance Global Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/reli#NASDAQ">RELI</a>) gained 24.6% to $0.46 after the company reported FY23 earnings.</li>
<li>Simulations Plus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slp#NASDAQ">SLP</a>) rose 22.5% to $47.12 after the company posted better-than-expected results for its second quarter.</li>
<li>Vast Renewables Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vste#NASDAQ">VSTE</a>) gained 22.3% to $8.81.</li>
<li>Sportsman&#39;s Warehouse Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwh#NASDAQ">SPWH</a>) gained 21.3% to $3.7950 following a narrower-than-expected quarterly loss.</li>
<li>Gorilla Technology Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grrr#NASDAQ">GRRR</a>) jumped 19% to $0.8729 after the company reported a year-over-year increase in FY23 sales results.</li>
<li>Levi Strauss &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/levi#NYSE">LEVI</a>) shares rose 18.3% to $22.10 after the company reported upbeat earnings for its first quarter and boosted its 2024 earnings guidance.</li>
<li>NOVONIX Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvx#NYSE">NVX</a>) gained 15.4% to $2.83.</li>
<li>Zeta Global Holdings Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zeta#NYSE">ZETA</a>) climbed 14.8% to $12.09 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight and raised its price target from $12 to $17.</li>
<li>Graphjet Technology (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gti#NASDAQ">GTI</a>) gained 13.3% to $8.17</li>
<li>MaxLinear, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mxl#NASDAQ">MXL</a>) gained 11.8% to $24.22. MaxLinear is expected to release its financial results for the first quarter 2024 after the closing bell on April 24, 2024.</li>
<li>Eiger BioPharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eigr#NASDAQ">EIGR</a>) gained 9.7% to $1.81. Eiger Biopharmaceuticals said on April 2, it received a notice from the Nasdaq that the company&rsquo;s common stock will be delisted from Nasdaq.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) shares gained 8.8% to $29.39 after jumping 27% on Wednesday.</li>
<li>Addex Therapeutics Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adxn#NASDAQ">ADXN</a>) shares rose 8.2% to $16.76. Addex Therapeutics shares gained 18% on Wednesday after the company and funds affiliated with Perceptive Advisors announced the launch of Neurosterix..</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 7.4% to $1,724.42 amid a rise in Bitcoin.</li>
<li>Enphase Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enph#NASDAQ">ENPH</a>) climbed 7% to $126.86.</li>
<li>HubSpot, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hubs#NYSE">HUBS</a>) gained 6% to $664.51 following a report suggesting Alphabet is in talks with advisors about a potential offer for the company.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) climbed 4% to $2.9223 after the company reported fourth-quarter results and issued FY25 guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>eFFECTOR Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eftr#NASDAQ">EFTR</a>) shares dipped 80.7% to $3.1801. The company announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer.</li>
<li>Keyarch Acquisition Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kych#NASDAQ">KYCH</a>) fell 34.5% to $5.94.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) fell 29.4% to $0.3601. View shares fell on Wednesday after the company filed for Chapter 11 bankruptcy.</li>
<li>Achilles Therapeutics plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achl#NASDAQ">ACHL</a>) declined 27% to $0.88 after the company reported fourth-quarter financial results. The company announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.</li>
<li>KWESST Micro Systems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kwe#NASDAQ">KWE</a>) fell 24.4% to $0.85 after the company announced a proposed US public offering.</li>
<li>AXT, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axti#NASDAQ">AXTI</a>) fell 22.2% to $3.85. Traders circulated J Capital short report.</li>
<li>XTI Aerospace, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtia#NASDAQ">XTIA</a>) fell 20.9% to $3.64 after gaining 31% on Wednesday.</li>
<li>DigiAsia Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/faas#NASDAQ">FAAS</a>) fell 20% to $5.37.</li>
<li>Lamb Weston Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lw#NYSE">LW</a>) declined 17.5% to $83.40 after the company reported weak third-quarter results and cut its FY24 outlook.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) dipped 17.5% to $0.0811.</li>
<li>Casa Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/casa#NASDAQ">CASA</a>) declined 16.3% to $0.0460. Casa Systems said the company and some units entered into asset purchase agreement with Lumine providing for sale and purchase of debtors&#39; Cloud/Ran APA assets.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) fell 15.2% to $0.1390. Kintara Therapeutics recently entered a merger agreement with TuHURA Biosciences.</li>
<li>Flora Growth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flgc#NASDAQ">FLGC</a>) fell 13.5% to $2.3095 after the company reported the launch of proposed underwritten public offering of common shares.</li>
<li>GCT Semiconductor Holding, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) fell 13.1% to $5.96.</li>
<li>SolarMax Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) dipped 10.9% to $11.75.</li>
<li>LAMF Global Ventures Corp. I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvc#NASDAQ">LGVC</a>) shares tumbled 10.2% to $9.97. LAMF Global Ventures Corp. I shares gained 3% on Wednesday after the company announced shareholders approved the previously announced business combination with Nuvo.</li>
<li>ARCA biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abio#NASDAQ">ABIO</a>) fell 8.9% to $2.96. ARCA Biopharma shares jumped 90% on Wednesday after the company and Oruka Therapeutics announced a merger agreement.</li>
<li>Aquestive Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aqst#NASDAQ">AQST</a>) fell 8.9% to $3.9850 after the company filed for an up to $250 million mixed shelf offering.</li>
<li>OneMedNet Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onmd#NASDAQ">ONMD</a>) shares fell 8.6% to $0.97. OneMedNet shares jumped 34% on Wednesday after the company completed a securities purchase agreement to provide up to $4.54 million in funding.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) fell 8.6% to $5.37.</li>
<li>Paramount Global (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/para#NASDAQ">PARA</a>) fell 8.2% to $12.40 following a report suggesting the Ellison-led bid would require the company to raise new equity.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38092036/bitcoin-tops-66-000-following-jobless-claims-data-ethena-emerges-as-top-gainer"> Bitcoin Tops $66,000 Following Jobless Claims Data; Ethena Emerges As Top Gainer</a>

Penny Stocks

ABIO

ACHL

ADXN

ALUR

AQST

AXTI

CADL

CASA

DXYZ

EFTR

EIGR

ENPH

FAAS

FLGC

GCTS

GRRR

HUBS

Kintara Therapeutics, Inc. - Common Stock

KTRA

KYCH

LEVI

LGVC

MGNX

MSTR

Nuveen California Dividend Advantage Municipal Fund 2

ONMD

PARA

RELI

RENT

SLNA

SMXT

SPWH

TCBP

TVGN

VIEW

VSTE

XTIA

ZETA

Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Throughout the last three months, 4 analysts have evaluated Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $44.5, a high estimate of $50.00, and a low estimate of $33.00. This upward trend is apparent, with the current average reflecting a 4.71% increase from the previous average price target of $42.50.
<img src="https://www.benzinga.com/files/images/story/2024/1712246413_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Staar Surgical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Staar Surgical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Staar Surgical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/STAA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Staar Surgical analyst ratings.</a>
<h2>Unveiling the Story Behind Staar Surgical</h2>
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses which are used in surgery that treat cataracts. The company offers two types of products which are Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
<h3>Staar Surgical: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Staar Surgical displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 19.09%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Staar Surgical's net margin is impressive, surpassing industry averages. With a net margin of 10.17%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Staar Surgical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.62%, the company showcases efficient use of assets and strong financial health.
Debt Management: Staar Surgical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For Staar Surgical

TVGN: 101% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38066837">Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development</a>
CADL: 62% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38088367">Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer</a>
STAA: 11% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/38087313">STAAR Surgical shares are trading higher after the company issued strong preliminary Q1 net sales guidance.</a>

Market-Moving News for April 4th

STAAR Surgical shares are trading higher after the company issued strong preliminary Q1 net sales guidance.

U.S. ICL sales expected to be&nbsp;$5 million&nbsp;for the quarter. This represents the Company&#39;s highest quarterly ICL sales in the U.S. since the Company obtained U.S. FDA approval of the EVO ICL in March 2022.&nbsp;&nbsp;Cash, cash equivalents and investments available for sale was approximately&nbsp;$248 million&nbsp;and accounts receivable was approximately&nbsp;$70 million&nbsp;as of March 29, 2024, as compared to&nbsp;$232.4 million&nbsp;and&nbsp;$94.7 million, respectively, at December 29, 2023. The Company expects to report complete&nbsp;first quarter&nbsp;financial results and discuss its fiscal 2024&nbsp;outlook&nbsp;during its quarterly earnings call on or about May 8, 2024.

STAAR Surgical Reports Preliminary Net Sales For Q1 To Be In Excess Of $77M (Est $72.134M); Now Expects FY24 Net Sales Can Be At Higher End Of Prior Outlook Range Of $335M-$340M (Est $337.208M)

STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Staar Surgical (STAA – Research Report), Ocugen (OCG...

Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Ocugen (OCGN) and Moderna (MRNA)

Analyst Young Li of Jefferies reiterated a Buy rating on Staar Surgical (STAA – Research Report), retaining the price target of $60.00. Young Li ha...

Staar Surgical Poised for Growth in Refractive Surgery Market, Maintains Buy Rating

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Staar Surgical (STAA – Research Report), Pliant Ther...

Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), Pliant Therapeutics (PLRX) and Crinetics Pharmaceuticals (CRNX)

STAAR Surgical GAAP EPS of -$0.07 beats by $0.03, revenue of $77.4M beats by $2.21M

Staar Surgical (STAA) just unveiled an announcement. On May 7, 2024, at 4:15 p.m. Eastern Time, key executives from the Company, including the Chai...

Staar Surgical Executives Discuss Q1 Results and 2024 Outlook

STAAR Surgical Company (STAA) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Staar Surgical (NASDAQ:<a href="https://investorplace.com/stock-quotes/staa-stock-quote/">STAA</a>) just reported results for the first quarter of 2024.<ul><li>Staar Surgical reported earnings per share of -7 cents. This was below the analyst estimate for EPS of 4 cents.</li><li>The company reported revenue of $77.36 million.</li><li>This was 3.27% better than the analyst estimate for revenue of $74.91 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/staa-stock-earnings-staar-surgical-for-q1-of-2024/">STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q1 2024

Needham analyst David Saxon has maintained their neutral stance on STAA stock, giving a Hold rating today. David Saxon's rating is based on a caref...

Staar Surgical: A Hold Rating Amidst Conservative Guidance and Modest Growth Prospects

In a report released today, Steven Lichtman from Oppenheimer maintained a Hold rating on Staar Surgical (STAA – Research Report). The company's sha...

Oppenheimer Sticks to Its Hold Rating for Staar Surgical (STAA)

CRNX

MRNA

OCGN

PLRX

Press Releases

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

STAAR Surgical to Participate in Two Upcoming Investor Conferences

STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024

STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024

STAAR Surgical to Report First Quarter Results on May 7, 2024

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Staar Surgical Stock (NASDAQ:STAA), Short Interest Report

People Also Watch